Monopar Therapeutics 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Monopar Therapeutics Inc. filed an amended annual report for 2025, correcting an audit report date and providing updated certifications, while revealing a strengthened financial position and ongoing pipeline development.
NASDAQ
Monopar Therapeutics reports progress in its Wilson disease and radiopharmaceutical oncology programs, backed by a recent $91.9 million capital raise and extended cash runway through 2027.
NASDAQ
10-K: Monopar Therapeutics Inc. Reports 2024 Results, Highlights ALXN1840 and Radiopharmaceutical Programs
Monopar Therapeutics Inc. files its 10-K report for the fiscal year ended December 31, 2024, detailing its financial status and progress in developing ALXN1840 for Wilson disease and its novel radiopharmaceutical programs for oncology.
NASDAQ
Monopar Therapeutics Inc.'s 2023 annual report highlights progress in its radiopharmaceutical program and ongoing clinical trials for camsirubicin, while also addressing financial challenges and compliance issues.